


## NCGC00092410

<b>Cat. No.:</b>	HY-114043		
<b>CAS No.:</b>	442898-34-2		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>27</sub> N <sub>3</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	353.46		
<b>Target:</b>	Glucosidase		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 41.67 mg/mL (117.89 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM		2.8292 mL	14.1459 mL	28.2917 mL
		5 mM		0.5658 mL	2.8292 mL	5.6583 mL
10 mM			0.2829 mL	1.4146 mL	2.8292 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.88 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	<p>NCGC00092410 is a potent, selective, and nonsugar glucocerebrosidase (GC) inhibitor, with an IC<sub>50</sub> of 31 nM. NCGC00092410 shows no activity against the related hydrolases at concentrations up to 77 μM. NCGC00092410, a GC chaperone, and increases the activity and lysosomal localization of glucocerebrosidase in mutant cell lines. NCGC00092410 can be used for the research of Gaucher disease<sup>[1]</sup>.</p>
<b>IC<sub>50</sub> &amp; Target</b>	<p>IC<sub>50</sub>: 31 nM (glucocerebrosidase)<sup>[1]</sup></p>
<b>In Vitro</b>	<p>NCGC00092410 (7.3-130 nM; 25 min) inhibits the GC activity at various substrate concentrations (10-150 μM) in a dose-dependent manner<sup>[1]</sup>.</p> <p>NCGC00092410 (55-40 μM; 2 d) increases the GC activity in the N370S mutant fibroblasts<sup>[1]</sup>.</p> <p>NCGC00092410 (40 μM; 60-72 h) increases the lysosomal localization of GC in gaucher fibroblasts<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

---

## REFERENCES

[1]. Zheng W, et, al. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13192-7.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA